Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

Remus Pharmaceuticals Ltd

Remus Pharma. |

Market Closed
₹817.60
+₹22.58 (+2.84%)
As on 22/11/26, 7:10 PM
Market Cap936.83 CR
Current Price₹817.6
High / Low₹1,039 / 580
PE Ratio20
Book Value₹297.95
Dividend Yield0.08%
ROCE18.42%
ROE---
Face Value₹2.00
Current Vol.900
Average Vol.---
ISININE0O5T01011
PB Ratio2.11
Debt to Equity0.08
Net Profit Margin5.41
Operating Margin7.42

REMUS - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹795₹791
₹817.6
Previous CloseToday's Open
₹580₹1,039
₹817.6
52W Low52W High
₹791Today's Open
₹795Previous Close
900Volume
₹58052W Low
₹1,03952W High

Ratios

No data available

About Company

  • Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat
  • Subsequently, Company converted in to a Public Company and changed to 'Remus Pharmaceuticals Limited' in January 2023
  • Remus Pharmaceuticals Limited is a global pharmaceutical Company focused on the marketing, distribution and export of niche, specialised and complex pharmaceutical formulations
  • With a presence across 40+ countries, it serve diverse healthcare markets through a growing portfolio spanning multiple therapeutic areas
  • The Company focuses on niche, specialised and critical-care formulations and has a strong
  • presence across 40+ countries in Latin America, Southeast Asia, the Middle East, CIS, Caribbean Islands, Eastern Europe and Africa
  • The core business of the Company into three categories, which comprise of Manufacturing, through loan licencse or on contract manufacturing bassis, of approved finished formulations and distribution of the same in various countries; Trading of Active Pharmaceutical Ingredients and Technical Consultancy on preparation of reports on pharmaceutical dossiers
  • The product portfolio comprises of therapeutic drugs like ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Anti-inflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocular-hypertension, Urology and Vitamin deficiency
  • The Pharma business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant
  • The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence and marketing of formulations through marketing network across geographies

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI44.17
SMA 20831.10
SMA 50890.75
SMA 100851.72
SMA 200772.57
SMA 10812.13
MACD_12_26_Days-25.33
EMA10Day815.94
EMA20Day835.25
EMA50Day860.80
MACD_12_26_9_Days0.20
EMA100Day845.93
EMA200Day822.52

Pivot Points

Volume Analysis

Delivery
Total Volume

Growth Rate

Revenue Growth37.60%
ROE15.22%
EBITDA Margin7.42%

All figures in ₹ Crores

Indicators202620252024
Revenue
853.63
620.36
212.50
Interest
1.47
1.46
0.48
Expenses
796.95
574.67
184.69
Financing Profit
63.37
50.67
33.21
Financing Margin %
7%
8%
16%
Other Income
6.69
4.98
5.40
Depreciation
2.76
1.87
0.90
Profit before tax
59.14
47.34
31.83
Tax %
22%
19%
18%
Net Profit
46.17
38.42
25.98
EPS in Rs
39.19
32.61
152.01
Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

📊

No Data Available

No Block Deals data available for this company.

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
07 Nov 2026
Interim 1 Dividend (₹1)
The Board has approved 01 st Interim Dividend of Re.1.00/- (Rupee One only) per equity share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the Financial Year 2026-27.
03 Nov 2026
29 Sept 2026
AGM
AGM
07 Sept 2026
22 Sept 2026
Final Dividend (₹0.5)
The Board has recommended final dividend of Rs. 0.50 (Fifty paise only) per Equity Share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the Financial Year 2025-26. Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 22-Sep-2026. As Per Nse Announcement Dated On 07.09.2026
20 May 2026
14 Nov 2025
Interim 1 Dividend (₹0.5)
The Board has approved 01st Interim Dividend of Rs. 0.50 (Fifty paise only) per equity share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the Financial Year 2025-26. The record date for the purpose of payment of Interim Dividend, as intimated earlier will be November 14, 2025.
10 Nov 2025
25 Sept 2025
AGM
AGM
02 Sept 2025
18 Sept 2025
Final Dividend (₹0.5)
The Board has recommended Dividend of Rs. 0.50 (Fifty paise only) per Equity Share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the Financial Year 2024-25, subject to the approval by shareholders of the Company at the ensuing Annual General Meeting ('AGM'). Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 18-Sep-2025. (As Per NSE Announcement Dated On : 02.09.2025)
17 May 2025
04 Jul 2025
Bonus Issue (1:1)
1:1 Bonus Issue of Equity Shares
30 Jun 2025
20 Nov 2024
Interim Dividend (₹1)
Interim Dividend for FY 2024-25 of 10% i.e., Re. 1.00 per equity share of face value of Rs. 10.00 each. The record date for the purpose of payment of Interim Dividend, as intimated earlier will be November 20, 2024
09 Nov 2024
20 Sept 2024
AGM
AGM
29 Aug 2024
06 Jun 2024
Bonus Issue (3:1)
3:1 Bonus Issue of Equity Shares
04 Jun 2024

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
818
963
26
3
24
0
5.41%
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 140 Results

Frequently Asked Questions

What is Share Price of Remus Pharmaceuticals Ltd?

The current share price of Remus Pharmaceuticals Ltd (Remus Pharma.) is ₹817.60. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the 52-week high and low of Remus Pharmaceuticals Ltd?

Remus Pharmaceuticals Ltd has a 52-week high of ₹1039.00 and a 52-week low of ₹580.00. This range shows the stock's price volatility over the past year.

What is the ROCE of Remus Pharmaceuticals Ltd?

The Return on Capital Employed (ROCE) of Remus Pharmaceuticals Ltd is 18.42%. ROCE measures how efficiently the company generates profits from its capital, indicating management effectiveness.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2